ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 1.35TCr 1.18TCr 1.09TCr 1.01TCr 1.92TCr 1,28700Cr 1.95TCr 13TCr 5.07TCr 63TCr 5.07TCr 4.97TCr 2,18000Cr | P/E 2026 * |
-22.7x | P/E 2027 * | -65x |
|---|---|---|---|---|---|
| Enterprise Value | 1.33TCr 1.16TCr 1.07TCr 995.85Cr 1.89TCr 1,26600Cr 1.92TCr 13TCr 4.99TCr 62TCr 4.99TCr 4.88TCr 2,14500Cr | EV / Sales 2026 * |
14.9x | EV / Sales 2027 * | 8.89x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 1.35TCr | |
| +1.70% | +7.41% | +2.50% | +8.22% | 4.99TCr | |
| +0.92% | +3.93% | +399.71% | +605.33% | 4.02TCr | |
| +1.89% | +8.32% | +26.06% | -6.35% | 3.46TCr | |
| +2.38% | +6.35% | +21.25% | +64.58% | 3.31TCr | |
| +3.96% | +10.67% | +8.30% | +40.44% | 2.75TCr | |
| +2.51% | +5.27% | - | - | 1.7TCr | |
| +2.58% | +5.79% | +73.44% | +133.27% | 1.59TCr | |
| +0.32% | +0.58% | +14.00% | +19.59% | 1.39TCr | |
| +5.63% | +59.76% | +1,820.34% | +785.83% | 1.33TCr | |
| Average | +2.32% | +11.97% | +295.70% | +206.36% | 2.73TCr | |
| Weighted average by Cap. | +2.15% | +9.54% | +191.03% | +177.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 89Cr 78Cr 72Cr 67Cr 126.9Cr 8.51TCr 128.82Cr 861.68Cr 334.98Cr 4.18TCr 335.35Cr 328.15Cr 14TCr | 150.51Cr 131.57Cr 120.92Cr 112.71Cr 213.77Cr 14TCr 217.02Cr 1.45TCr 564.31Cr 7.04TCr 564.94Cr 552.81Cr 24TCr |
| Net income | -60Cr -52Cr -48Cr -45Cr -85Cr -5.7TCr -86Cr -577.17Cr -224.37Cr -2.8TCr -224.62Cr -219.8Cr -9.65TCr | -20Cr -17Cr -16Cr -15Cr -28Cr -1.89TCr -29Cr -191.5Cr -74Cr -929.29Cr -75Cr -73Cr -3.2TCr |
| Net Debt | -22Cr -19Cr -18Cr -16Cr -31Cr -2.09TCr -32Cr -212.21Cr -82Cr -1.03TCr -83Cr -81Cr -3.55TCr | -14Cr -12Cr -11Cr -10Cr -20Cr -1.32TCr -20Cr -133.26Cr -52Cr -646.67Cr -52Cr -51Cr -2.23TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
